Galapagos NV Share Price Euronext Bruxelles
Equities
GLPG
BE0003818359
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
31/05 | Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment | MT |
31/05 | Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug | MT |
Sales 2024 * | 31Cr 34Cr 0 2.81TCr | Sales 2025 * | 30Cr 33Cr 0 2.72TCr | Capitalization | 163.82Cr 176.23Cr 0 15TCr |
---|---|---|---|---|---|
Net income 2024 * | -1.3Cr -1.4Cr - -116.85Cr | Net income 2025 * | -7.1Cr -7.64Cr - -638.17Cr | EV / Sales 2024 * | -5.53 x |
Net cash position 2024 * | 336.78Cr 362.3Cr 0 30TCr | Net cash position 2025 * | 297.27Cr 319.8Cr 0 27TCr | EV / Sales 2025 * | -4.41 x |
P/E ratio 2024 * |
-42.2
x | P/E ratio 2025 * |
-15.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.64% |
Latest transcript on Galapagos NV
Managers | Title | Age | Since |
---|---|---|---|
Paulus Stoffels
CEO | Chief Executive Officer | 62 | 01/22/01 |
Thad Huston
DFI | Director of Finance/CFO | 54 | 01/23/01 |
Investor Relations Contact | - | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Dickinson
BRD | Director/Board Member | 54 | 27/03 |
Jérôme Contamine
BRD | Director/Board Member | 66 | 26/22/26 |
Simon Sturge
BRD | Director/Board Member | 65 | 19/23/19 |
1st Jan change | Capi. | |
---|---|---|
+51.85% | 5.79TCr | |
+41.93% | 4.03TCr | |
-5.25% | 3.99TCr | |
-5.16% | 2.85TCr | |
+12.79% | 2.64TCr | |
-20.18% | 1.93TCr | |
+30.88% | 1.24TCr | |
+0.61% | 1.22TCr | |
+25.06% | 1.22TCr |
- Stock Market
- Equities
- GLPG Stock
- GLPG Stock